Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Henan Cancer Hospital)"
Count: 147
Selected: 0
NCT IDTitle
NCT03881774Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
NCT03881761CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
NCT02395705Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
NCT02621333Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
NCT05189483Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.
NCT05177068Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
NCT05176080Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
NCT05162898Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
NCT05083208PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05063136Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
NCT05023720Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer
NCT05013697TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
NCT04948125Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
NCT04938297Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
NCT04901754Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
NCT04891900TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
NCT04891016Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
NCT04778800A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
NCT04737889Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
NCT04718038Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
NCT04681287Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
NCT04675866Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
NCT04668365Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
NCT04664972The TP Regimen in the Treatment of Early Triple Negative Breast Cancer
NCT04660097Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
NCT04615312A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
NCT04553939Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
NCT04547907Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer, A Multicenter, Randomized, Phase III Clinical Trial
NCT04538833GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel
NCT04433156VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
NCT04430361the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
NCT04341857PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma
NCT04331626Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
NCT04293276Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
NCT04280822Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
NCT04268108L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
NCT04263935Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
NCT04229849Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
NCT04223583Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule
NCT04222790A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity
NCT04214626R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
NCT04213898SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
NCT04199559Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
NCT04199520Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Patients With Stage Ⅳ Breast Cancer
NCT04138212Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
NCT04087252An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment
NCT04067037Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
NCT04063683Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).
NCT04055792Sintilimab Combined With Anlotinib in Third Line or Beyond Among Advanced SCLC Patients
NCT04034667Study of CT and MR in the Lung Cancer